KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for TherapeuticsMD (TXMD) over the last 15 years, with Q3 2025 value amounting to $51000.0.

  • TherapeuticsMD's Gains from Investment Securities fell 1774.19% to $51000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $51000.0, marking a year-over-year decrease of 1774.19%. This contributed to the annual value of $57000.0 for FY2024, which is 6503.07% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Gains from Investment Securities is $51000.0, which was down 1774.19% from $51000.0 recorded in Q2 2025.
  • TherapeuticsMD's Gains from Investment Securities' 5-year high stood at $23.5 million during Q2 2021, with a 5-year trough of -$721000.0 in Q3 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $62500.0 (2024), whereas its average is $2.5 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 13566923.08% in 2021, then plummeted by 46598.98% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Gains from Investment Securities stood at $353000.0 in 2021, then tumbled by 51.27% to $172000.0 in 2022, then skyrocketed by 1243.6% to $2.3 million in 2023, then plummeted by 97.53% to $57000.0 in 2024, then decreased by 10.53% to $51000.0 in 2025.
  • Its Gains from Investment Securities stands at $51000.0 for Q3 2025, versus $51000.0 for Q2 2025 and $52000.0 for Q1 2025.